SCHEMBL62817

SCHEMBL62817

CCOC(=O)c1nc2n(c(=O)c1O)CCC1CCC2(NC(=O)OCc2ccccc2)C1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.37
OGFRL1 Q5TC84 3/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
HPGD P15428 1/20 0.36
FKBP1A P62942 2/20 0.35
ADORA3 P0DMS8 5/20 0.34
ELANE P08246 1/20 0.34
KDM4E B2RXH2 1/20 0.34
CTSK P43235 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
RORC P51449 1/20 0.34
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63621 0.93 ROCK2 (0.38) ROCK2OGFRL1OPRM1OPRD1OPRK1
SCHEMBL63542 0.91 HPGD (0.38) ROCK2OGFRL1OPRM1OPRD1OPRK1
SCHEMBL52246 0.89 HPGD (0.37) ROCK2OGFRL1OPRM1OPRD1OPRK1
SCHEMBL62151 0.88 ADORA3 (0.37) ROCK2OGFRL1OPRM1OPRD1OPRK1
SCHEMBL51543 0.86 ROCK2 (0.38) ROCK2OGFRL1OPRM1OPRD1OPRK1
SCHEMBL87293 0.85 TSHR (0.33) OGFRL1OPRM1OPRD1OPRK1HPGD
SCHEMBL63101 0.83 KCNH2 (0.43) FKBP1AMAPTL3MBTL1MEN1LMNA
SCHEMBL52276 0.83 ROCK2 (0.36) ROCK2OGFRL1OPRM1OPRD1OPRK1
SCHEMBL63519 0.82 OGFRL1 (0.41) ROCK2OGFRL1OPRM1OPRD1OPRK1
SCHEMBL63048 0.82 HPGD (0.36) ROCK2HPGDKDM4ERORCMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG ROCK2 1690/4885OGFRL1 3981/4885OPRM1 3627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.